Robert M. Califf

Adjunct Professor of Medicine
Donald F. Fortin, M.D. Distinguished Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Publications

Kaul, Padma, Shelby D. Reed, Adrian F. Hernandez, Jonathan G. Howlett, Justin A. Ezekowitz, Yanhong Li, Yinggan Zheng, et al. “Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States.” Jacc Heart Fail 1, no. 6 (December 2013): 523–30. https://doi.org/10.1016/j.jchf.2013.07.004.

PMID
24622005
Full Text

Richesson, Rachel L., W Ed Hammond, Meredith Nahm, Douglas Wixted, Gregory E. Simon, Jennifer G. Robinson, Alan E. Bauck, et al. “Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory.” J Am Med Inform Assoc 20, no. e2 (December 2013): e226–31. https://doi.org/10.1136/amiajnl-2013-001926.

PMID
23956018
Full Text

Richesson, Rachel L., Shelley A. Rusincovitch, Douglas Wixted, Bryan C. Batch, Mark N. Feinglos, Marie Lynn Miranda, W Ed Hammond, Robert M. Califf, and Susan E. Spratt. “A comparison of phenotype definitions for diabetes mellitus.” J Am Med Inform Assoc 20, no. e2 (December 2013): e319–26. https://doi.org/10.1136/amiajnl-2013-001952.

PMID
24026307
Full Text

Green, Jennifer B., M Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, and Rury R. Holman. “Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.” Am Heart J 166, no. 6 (December 2013): 983-989.e7. https://doi.org/10.1016/j.ahj.2013.09.003.

PMID
24268212
Full Text

Eggers, Kai M., Paul W. Armstrong, Robert M. Califf, Nina Johnston, Maarten L. Simoons, Per Venge, and Stefan K. James. “Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome.” Clin Biochem 46, no. 16–17 (November 2013): 1655–59. https://doi.org/10.1016/j.clinbiochem.2013.08.014.

PMID
24012697
Full Text

Latini, Roberto, Lidia Staszewsky, Jie-Lena Sun, M Angelyn Bethel, Marcello Disertori, Steven M. Haffner, Rury R. Holman, et al. “Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.” Am Heart J 166, no. 5 (November 2013): 935-40.e1. https://doi.org/10.1016/j.ahj.2013.08.012.

PMID
24176451
Full Text

Shah, Bimal R., Kevin L. Thomas, Sharon Elliot-Bynum, Kristin Thomas, Katrina Damon, Nancy Allen LaPointe, Sarah A. Calhoun, et al. “Check it, change it: a community-based intervention to improve blood pressure control.” Circ Cardiovasc Qual Outcomes 6, no. 6 (November 2013): 741–48. https://doi.org/10.1161/CIRCOUTCOMES.113.000148.

PMID
24221840
Full Text

Ezekowitz, Justin A., Jeffrey A. Bakal, Cynthia M. Westerhout, Robert P. Giugliano, Harvey White, Matyas Keltai, Dorairaj Prabhakaran, et al. “The relationship between meteorological conditions and index acute coronary events in a global clinical trial.” Int J Cardiol 168, no. 3 (October 3, 2013): 2315–21. https://doi.org/10.1016/j.ijcard.2013.01.061.

PMID
23416014
Full Text

Pages